Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal liver function tests should elicit clinical suspicion of PBC, a so-called “common rare” disease. While PBC disproportionately affects middle-aged White women, it is increasingly being seen in men and in African American and Asian American populations. The increasing prevalence of PBC, coupled with disparities in diagnosis and treatment access, highlight the urgent need for improved clinical awareness.
In this CME Outfitters recorded webcast, expert faculty will assess the burden of delayed diagnosis on patients with PBC, review evidence-based strategies for early, non-invasive detection, and discuss contemporary clinical pathways for treatment, including recent FDA-approved options. The program will also emphasize interdisciplinary collaboration and shared decision-making to empower patients and improve health outcomes through informed and equitable care. Learners will be equipped with evidence-based tools to help incorporate diagnostic and treatment approaches at the point of care.
At the conclusion of this activity, learners will be able to better:
This educational activity is supported by an independent educational grant from Gilead Sciences, Inc.
Primary: Hepatologists, gastroenterologists
Secondary: Primary care physicians (PCPs)/OBGYNs, physician associates (PAs), nurse practitioners (NPs), registered nurses, and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-099-H01-P).
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Kowdley reports the following financial relationships:
Consultant: 89bio, Inc.; Arbormed Pharmaceuticals; Boehringer Ingelheim; CymaBay Therapeutics Inc.; Genfit; Gilead Sciences, Inc.; GSK; HighTide Therapeutics, Inc.; Inipharm; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals; Mirum; NGM Biopharmaceuticals; Novo Nordisk; Orphalan; Pfizer Inc.; and Zydus Pharmaceuticals, Inc.
Grants: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Support: 89bio, Inc.; Akero Therapeutics, Inc.; AstraZeneca; Boston Pharmaceuticals; Boehringer Ingelheim; Corcept Therapeutics, Inc.; Gilead Sciences, Inc.; GSK; Hanmi Pharmaceutical; Intercept Pharmaceuticals, Inc.; Inventiva; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals; Mirum, NGM Biopharmaceuticals; Novo Nordisk; Pfizer Inc.; Pliant Therapeutics, Inc.; Terns Pharmaceuticals, Inc.; Viking Therapeutics; and Zydus Pharmaceuticals, Inc.
Speakers Bureau: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Ipsen Pharma
Other financial or material support: Royalties: UpToDate
Dr. Gulamhusein reports the following financial relationships:
Advisory Board: Cymabay Therapeutics, Inc. and Gilead Sciences, Inc.
Consultant: Advanz Pharma
Grants: Calliditas Therapeutics; Cymabay Therapeutics, Inc.; Genkyotex Suisse SA; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Novartis
Ms. Morais reports no financial relationships to disclose.
Dr. Werner reports the following financial relationships:
Speakers Bureau: Madrigal Pharmaceuticals
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).
WCV-089-120924-47